Patent: 9,181,337
✉ Email this page to a colleague
Summary for Patent: 9,181,337
Title: | Modulated lysine variant species compositions and methods for producing and using the same |
Abstract: | The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF.alpha. is detrimental, are also provided. |
Inventor(s): | Subramanian; Kartik (Northborough, MA), Perez Thiele; Mayda (Vega Alta, PR), Zeng; Xiaobei (Carolina, PR), Wong; Chee Furng (Singapore, SG), Kaymakcalan; Zehra (Westborough, MA), Jing; Ying (Wellesley, MA), Chumsae; Christopher (North Andover, MA) |
Assignee: | AbbVie, Inc. (North Chicago, IL) |
Application Number: | 14/077,988 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,181,337 |
Patent Claims: | see list of patent claims |
Details for Patent 9,181,337
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2033-10-18 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2033-10-18 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2033-10-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |